Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Announces Simplified New Process for Drug Delisting
The Ministry of Health, Labor and Welfare (MHLW) issued a notification on August 7 announcing simplified new rules for removing ethical drugs from the NHI price list. The new process will be applied beginning with products for which supply discontinuation…
To read the full story
Related Article
- Japan to Delete 16 Drugs from NHI Price List under New Streamlined Process
June 19, 2025
- First Drug Delisting in Simplified Process Slated for March-End 2026: MHLW
September 10, 2024
- How Will Simplified Delisting, Elective Care Affect G1 Withdrawal Scheme?
August 7, 2024
- Simplified Delisting to Be Allowed for Generics with Low Market Share from September: MHLW
May 13, 2024
- MHLW Proposes Simplified Generic Delisting Scheme
April 22, 2024
- Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
March 19, 2024
REGULATORY
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
- MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…